Bosulif 100 mg Film-Coated Tablets: Uses, Dosing and Safety
Quick summary Bosulif 100 mg film-coated tablets contain bosutinib and are used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Dosing is individualized, treatment is usually taken with food, and regular...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Bosulif 100 mg film-coated tablets contain bosutinib and are used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Dosing is individualized, treatment is usually taken with food, and regular monitoring is important for safety and response.
This article is for general information only and does not replace the official patient leaflet or advice from a doctor, pharmacist, or oncology team. Do not use it to diagnose a condition or to change any treatment plan.
What Bosulif 100 mg film-coated tablets are used for
Bosulif is a medicine used for Ph+ CML. The active ingredient is bosutinib. It is described in the source content as a treatment option for patients with this type of leukemia, including people who have had previous treatment resistance or intolerance.
The tablet form is film-coated, which may make it easier to swallow.
How Bosulif is prescribed
Prescribing Bosulif depends on the patient’s diagnosis, disease phase, and treatment history. The source content notes that doctors consider factors such as:
- Whether the CML is in the chronic or accelerated phase
- Previous resistance or intolerance to treatment
- The patient’s overall health status
Because treatment is individualized, the dose may be adjusted over time based on response and tolerability.
Dosing and administration
The source content states that the initial dose is often 400 mg daily for newly diagnosed patients and 500 mg daily for patients with resistance or intolerance to prior therapy.
Bosulif should be taken with food, as this is noted to help absorption and may reduce gastrointestinal discomfort.
Do not change the dose on your own. Any dose adjustment should be made by the prescribing clinician.
| Topic | What the source content says |
|---|---|
| Active ingredient | Bosutinib |
| Main use | Treatment of Ph+ CML |
| Typical starting dose mentioned | 400 mg daily or 500 mg daily, depending on treatment history |
| How to take it | With food |
| Dose changes | May be adjusted for response or side effects |
Common side effects mentioned in the source
The content provided lists the following common side effects:
- Low white blood cell counts
- Fatigue and weakness
- Nausea and diarrhea
- Raised liver enzymes
Skin reactions are also mentioned as possible and may need medical attention. Regular monitoring is important so that any problems can be identified early.
How Bosulif compares with other treatments
The source content describes Bosulif as a treatment that may be useful, especially when other therapies have not worked well. It also notes that it is available as a film-coated tablet and has been studied for efficacy and safety in CML.
Any comparison with other medicines should be made by the treating specialist, since the best option depends on the patient’s disease features and treatment history.
What patients should know before and during treatment
People taking Bosulif are advised in the source content to follow the prescription exactly and to report unusual symptoms to their doctor. Keeping a record of symptoms can help during follow-up visits.
Monitoring is especially important because treatment may need adjustment if side effects become significant.
Use in children
The source content states that Bosulif has been approved for use in children older than one year with Ph+ CML. It also notes that dosing and monitoring are especially important in this age group and should be supervised by a healthcare professional.
Parents and caregivers should review the official leaflet and speak with the child’s treatment team about what to watch for during therapy.
Cost and access considerations
The article source mentions that cost can be a concern. It suggests checking insurance coverage and asking about assistance programs or other support options. Because pricing and access vary, patients should confirm details with their pharmacy, insurer, or care team.
Safety reminder
Contact a healthcare professional promptly if side effects become severe, if new symptoms appear, or if there are concerns about how the medicine is being taken. Always rely on the official product information and the prescribing team for personal guidance.
Frequently asked questions
▸ How is Bosulif prescribed?
It is prescribed based on the patient’s diagnosis, disease phase, prior treatment history, and overall health. The dose is individualized by the doctor.
▸ What are the common side effects of Bosulif?
The source content lists low white blood cell counts, fatigue, nausea, diarrhea, raised liver enzymes, and possible skin reactions.
▸ Should Bosulif be taken with food?
Yes. The source content says it should be taken with food to help absorption and reduce gastrointestinal effects.
▸ Is Bosulif used in children?
The source content says it has been approved for children older than one year with Ph+ CML, with careful supervision and monitoring.
▸ Is Bosulif a chemotherapy drug?
The source content describes it as a targeted therapy rather than a traditional chemotherapy medicine.
▸ What should I do if I notice side effects?
Report them to the prescribing doctor or oncology team, especially if they are severe, persistent, or unusual.
Key takeaways
Bosulif 100 mg film-coated tablets contain bosutinib and are used for Ph+ CML. The dose is individualized, food intake matters, and ongoing monitoring is part of safe treatment. For the most accurate instructions, always check the official leaflet and speak with the prescribing clinician or pharmacist.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Bosulif (bosutinib) official patient information leaflet
- European Medicines Agency: Bosulif overview
- National Cancer Institute: Chronic Myeloid Leukemia
- Leukemia & Lymphoma Society: CML information
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.